BioNTech : First Quarter 2024 Financial Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MAY 2024

COMMISSION FILE NUMBER 001-39081

BioNTech SE

(Translation of registrant's name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

[phone]

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On May 6, 2024, BioNTech SE (the "Company") provided a development update and reported its financial results for the three months ended March 31, 2024. The interim condensed consolidated financial statements as well as the operating and financial review and prospects of the Company for the three months ended March 31, 2024 are attached hereto as Exhibit 99.1 and shall be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and incorporated by reference herein.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By: /s/ Jens Holstein

Name: Jens Holstein

Title: Chief Financial Officer

Date: May 6, 2024

EXHIBIT INDEX

Exhibit

Description of Exhibit

99.1 Quarterly Report for the Three Months Ended March 31, 2024

Exhibit 99.1

BioNTech SE

Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2024

Exhibit 99.1

Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is [phone]. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, [phone].

Exhibit 99.1

Unaudited Interim Condensed Consolidated Financial Statements

Interim Condensed Consolidated Statements of Profit or Loss	1
Interim Condensed Consolidated Statements of Comprehensive Income	2
Interim Condensed Consolidated Statements of Financial Position	3
Interim Condensed Consolidated Statements of Changes in Stockholders' Equity	4
Interim Condensed Consolidated Statements of Cash Flows	5
Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements	6
1	Corporate Information	6
2	Basis of Preparation, Significant Accounting Policies and further Accounting Topics	6
3	Revenues from Contracts with Customers	7
4 Income and Expenses	8
5 Income Taxes	9
6	Financial Assets and Financial Liabilities	11
7	Issued Capital and Reserves	14
8 Share-Based Payments	14
9	Contingencies	15
10 Related Party Disclosures	18
11 Events after the Reporting Period	18

Operating and Financial Review and Prospects

Operating Results	20
Liquidity and Capital Resources	40
Risk Factors	43

Unaudited Interim Condensed Consolidated Financial Statements

Interim Condensed Consolidated Statements of Profit or Loss

		Three months ended
		March 31,
		2024		2023
(in millions €, except per share data)	Note	(unaudited)		(unaudited)
Revenues	3	187.6		1,277.0
Cost of sales	4.1	(59.1)		(96.0)
Research and development expenses	4.1	(507.5)		(334.0)
Sales and marketing expenses	4.1	(15.6)		(12.2)
General and administrative expenses	(1)	(117.0)		(111.8)
	4.1
Other operating expenses (1)	4.2	(23.9)		(125.7)
Other operating income	4.3	28.3		57.1
Operating income / (loss)		(507.2)		654.4
Finance income	4.4	180.1		82.3
Finance expenses	4.4	(4.7)		(29.0)
Profit / (Loss) before tax		(331.8)		707.7
Income taxes	5	16.7		(205.5)
Profit / (Loss) for the period		(315.1)		502.2
Earnings / (Loss) per share
Basic earnings / (loss) for the period per share	(1.31)		2.07
Diluted earnings / (loss) for the period per share	(1.31)		2.05

1. Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (please see Note 4.2 for further details).

The accompanying notes form an integral part of these interim consolidated financial statements.

1

Interim Condensed Consolidated Statements of Comprehensive Income

		Three months ended
		March 31,
		2024		2023
(in millions €)	Note	(unaudited)		(unaudited)
Profit / (Loss) for the period		(315.1)		502.2
Other comprehensive income
Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax
Exchange differences on translation of foreign operations		15.4		(2.1)
Net gain on cash flow hedges		-		1.7
Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent		15.4		(0.4)
periods
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax
Net gain on equity instruments designated at fair value through other comprehensive income		6.9		-
Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods		6.9		-
Other comprehensive income / (loss) for the period, net of tax		22.3		(0.4)
Comprehensive income / (loss) for the period, net of tax		(292.8)		501.8

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

2

Interim Condensed Consolidated Statements of Financial Position

		March 31,	December 31,
(in millions €)		2024	2023
Assets	Note	(unaudited)
Non-current assets
Goodwill		368.7	362.5
Other intangible assets		821.7	804.1
Property, plant and equipment		802.6	757.2
Right-of-use assets		228.3	214.4
Other financial assets	6	1,587.2	1,176.1
Other non-financial assets		83.2	83.4
Deferred tax assets		91.0	81.3
Total non-current assets		3,982.7	3,479.0
Current assets
Inventories		345.4	357.7
Trade and other receivables	6	1,639.8	2,155.7
Contract assets		12.1	4.9
Other financial assets	6	6,689.9	4,885.3
Other non-financial assets		337.0	280.9
Income tax assets		273.3	179.1
Cash and cash equivalents		8,976.6	11,663.7
Total current assets		18,274.1	19,527.3
Total assets		22,256.8	23,006.3
Equity and liabilities
Equity
Share capital		248.6	248.6
Capital reserve		1,228.9	1,229.4
Treasury shares		(10.8)	(10.8)
Retained earnings		19,448.2	19,763.3
Other reserves		(946.7)	(984.6)
Total equity		19,968.2	20,245.9
Non-current liabilities
Lease liabilities, loans and borrowings	6	205.0	191.0
Other financial liabilities	6	40.6	38.8
Provisions		8.8	8.8
Contract liabilities		379.2	398.5
Other non-financial liabilities		9.6	13.1
Deferred tax liabilities		39.4	39.7
Total non-current liabilities		682.6	689.9
Current liabilities
Lease liabilities, loans and borrowings	6	31.3	28.1
Trade payables and other payables	6	298.8	354.0
Other financial liabilities	6	152.4	415.2
Income tax liabilities		353.2	525.5
Provisions		247.0	269.3
Contract liabilities		361.3	353.3
Other non-financial liabilities		162.0	125.1
Total current liabilities		1,606.0	2,070.5
Total liabilities		2,288.6	2,760.4
Total equity and liabilities		22,256.8	23,006.3

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.